CLEANprocesses
Financiado
Gaining an in depth understanding of the technical feasibility and commercializa...
Gaining an in depth understanding of the technical feasibility and commercialization potential for the cold active amylase enzyme
CLEANprocesses (CoLd-active Enzymes and New sustainable Processes) will analyse the technical feasibility of a cold-active amylase enzyme as well as its commercial potential in various markets.
Enzymes are a key ingredient in man...
CLEANprocesses (CoLd-active Enzymes and New sustainable Processes) will analyse the technical feasibility of a cold-active amylase enzyme as well as its commercial potential in various markets.
Enzymes are a key ingredient in many consumer products, such as food & drinks, textile, pharmaceuticals and detergents, and the enzyme market has become a multibillion dollar industry worldwide. For decades, it has been a goal for enzyme producers to discover truly cold-active enzymes, due to their performance at low temperature industrial processes resulting in significant reduction in energy and costs. However until now, results have been insufficient, as only partially cold-active enzymes have been achieved.
The cold-active enzymes on the market are mainly active at temperatures down to 30° and the best in class is active down to 16°. But if the goal is to be able to use these enzymes in tap water with a temperature around 7°, there is still a long way to go as even the best in class will be almost inactivated at this level.
Coldzymes (CZ) is the first company in the world to discover and develop truly cold-active enzymes with industrial relevance and potential. These stem from ikaite pillars in Greenland, which are made up of unusual minerals that precipitate when ion-rich spring water from Greenland mixes with seawater. In particular, CZ has discovered the α-amylase AmyI3C6, which has already been proven in cold wash detergents. It acts optimally at 5-20°C and still maintains over 70% of its activity at 0-1℃.
The market for enzymes is global, and the top three enzyme producers hold app. 75 % of the market share. CZ will develop and test the cold-active AmyI3C6 before selling the DNA sequence to the large enzyme producers. In turn CZ will receive royalties for the sales of the AmyI3C6, as the enzyme producers will include it in their portfolios on equal terms with their other enzymes. This business model entails that the enzyme is commercialised broadly.
ver más
Duración del proyecto: 6 meses
Fecha Inicio: 2018-05-02
Fecha Fin: 2018-11-30
Fecha Fin: 2018-11-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2018-11-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020:
SME instrument
Cerrada
hace 6 años
Presupuesto
El presupuesto total del proyecto asciende a
71K€
Líder del proyecto
NUNAZYMES APS
No se ha especificado una descripción o un objeto social para esta compañía.
264.65K€ |
Participante